Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-26

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators want to understand more about what kinds of health problems are caused by histiocytosis, what happens as a result of different treatments, and how ECD affects people's lives, their feelings and their attitudes. The investigators also want to learn how these things change over time for people with these conditions. To try to figure this out, doctors would like to collect information about people who have histiocytosis and how they are treated for this disease.

Some participants will be asked to complete a brief interview over the telephone. Only a limited number of interviews will take place, and not everyone will be asked to participate in the interview. It is okay if the participant does not want to participate in the interview portion. If this is the case, the participant should let the study team member know when contacted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Subtypes and Prognostic Factors in Erdheim-Chester Disease

NCT06317246

Erdheim-Chester Disease

RECRUITING NA

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

NCT01417520

Myelofibrosis Gaucher Disease Pulmonary Fibrosis +2 more

COMPLETED

Biomarkers in Systemic Histiocytosis

NCT07157683

Systemic Histiocytosis (Disorder)

NOT_YET_RECRUITING

Duke Scleroderma Clinic Patient Registry

NCT02851875

Scleroderma Systemic Sclerosis

TERMINATED

Study of Skin Tumors in Tuberous Sclerosis

NCT00001975

Tuberous Sclerosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erdheim-Chester Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Erdheim-Chester Disease and Other Histiocytoses

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Erdheim-Chester Disease, Langerhans cell histiocytosis, Rosai Dorfman disease, or another histiocytic neoplasm by either 1) documented histopathologic establishing ECD or HN or 2) documented histopathologic findings compatible with Erdheim-Chester disease or HN in the context of corroborating clinical and/or radiologic findings or 3) documented radiologic findings, in the absence of a biopsy having been performed or yielding evaluable tissue, that are felt by the Principal Investigator to unequivocally represent an ECD/HN diagnosis given the clinical context or 4) self reported with supporting documentation upon medical record collection.
* Proficiency in English, in the determination of the Investigator or by self report.
* Willing to have historical and future HN-related health records sent to Registry review.